BRAF and metastatic melanoma: Trametinib plus dabrafenib significantly prolonged PFS and OS, improved objective response rates and preserved health-related quality of life to a greater extent than dabrafenib (in the double-blind COMBI-d study) and vemurafenib (in the open-label COMBI-v study) in two large, randomized, Phase III studies in treatment-naïve patients with unresectable or metastatic melanoma with BRAF (V600E/K) mutation [109].